Docetaxel in the management of advanced or metastatic urothelial tract cancer.

Abstract

Phase II studies of single-agent docetaxel (Taxotere) yielded promising results in advanced or metastatic transitional cell carcinoma (TCC) of the urothelium. Antitumor responses have been demonstrated in previously treated and chemotherapy-naive TCC patients, as well as in a subgroup of patients with renal impairment unable to receive traditional cisplatin-based regimens. Investigations of docetaxel-containing doublet and triplet drug combinations in the first-line setting have been pursued. When combined with cisplatin in previously untreated patients, response rates of 52% to 60% have been achieved, with median overall survival of 8 to 13.6 months. Triplet drug combinations of the docetaxel/platinum base have been investigated, when the addition of an anthracycline (doxorubicin or epirubicin [Ellence]) or of gemcitabine (Gemzar) has proven feasible, and has resulted in favorable efficacy findings. Non-platinum-containing regimens such as docetaxel/gemcitabine are also being studied. Randomizedphase III trials of a docetaxel-containing regimen in comparison with established regimens are ongoing, and additional studies are warranted to determine if overall long-term survival of TCCpatients can be improved.

• Authors: Christopher Logothetis, Randall Millikan
• Journal: Oncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 16 Issue 6 Suppl 6 Pg. 107-11 (Jun 2002) ISSN: 0890-9091 [Print] United States
• PMID: 12108893 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents, Phytogenic
• Taxoids
• Deoxycytidine
• Docetaxel
• Paclitaxel
• Cisplatin
• Gemcitabine

Topics

• Antineoplastic Agents, Phytogenic (adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Transitional Cell (drug therapy, mortality)
• Cisplatin (administration & dosage)
• Clinical Trials, Phase II as Topic
• Deoxycytidine (administration & dosage, analogs & derivatives)
• Docetaxel
• Humans
• Paclitaxel (adverse effects, analogs & derivatives, therapeutic use)
• Taxoids
• Urologic Neoplasms (drug therapy, mortality)
• Gemcitabine